A ‘stronger, more holistic’ impact
May 19, 2017
COMPUTATIONAL BIOMEDICINE
Every patient’s cancer is different. Olivier Elemento, associate director of the HRH Prince Alwaleed Bin Talal Bin Abdulaziz Al-Saud Institute for Computational Biomedicine at Weill Cornell Medicine, hopes to help provide them with highly individualized and precisely targeted treatment.
Three-Pronged Approach Key to Precision Medicine
March 22, 2017
Combining genetic information from a patient’s tumor cells with three-dimensional cell cultures grown from these tumors and rapidly screening approved drugs can identify the best treatment approaches in patients for whom multiple therapies have failed, according to a new study led by Weill Cornell Medicine investigators.
Research Reveals Gene Mutation as Driver of Prostate Cancer Subtype
March 13, 2017
A newly discovered genetic mutation that is found in a subtype of prostate cancer is integral to the disease’s development and growth, according to research from Weill Cornell Medicine scientists. Their findings could pave the way for new targeted treatment approaches.
Department of Defense Impact Award Funds Prostate Cancer Study
March 8, 2017
Weill Cornell Medicine researchers will receive a grant from the Department of Defense to conduct an in-depth study of the molecular machinery driving the most aggressive form of prostate cancer.
Bishoy Faltas, MD, named AACR NextGen Star
March 1, 2017
Going Virtual at Cornell’s eLab
February 21, 2017
Entrepreneurship at Cornell (eLab) is a diverse, university-wide program that finds and fosters the entrepreneurial spirit in participants from every college, every field, and in every stage of life. Grounded in the belief that individuals who exhibit an entrepreneurial spirit and have acquired entrepreneurial knowledge can add significant value to any working environment from the smallest startup to the largest business, from non-profits to government agencies.
API-based genomics databank facilitates personalized medicine
December 1, 2016
Genomic testing is becoming an increasingly common starting place for the development of personalized medicine treatments for patients with a variety of hard-to-treat diseases, especially cancer, but organizations often struggle with interpreting and analyzing a glut of raw data produced by sequencing initiatives.
Tracing Cancer’s Roots
November 22, 2016
In a light-filled office, two young physician-scientists study how cancer forms, spreads, and recurs after remission. They meet once or twice a week where—amid leftover take-out containers and white-boarded walls—they write code, work through complex problems, and share recent triumphs and challenges.
EXaCT-1 Precision Medicine Cancer Test Validated for Clinical Usage
October 3, 2016
A powerful next-generation genome-sequencing test developed at Weill Cornell Medicine can detect mutations that guide precision cancer treatment with over 95 percent accuracy, according to new research.